• Corpus ID: 13071349

Soft tissue sarcomas of adults: state of the translational science.

  title={Soft tissue sarcomas of adults: state of the translational science.},
  author={Ernest C. Borden and Laurence H. Baker and Robert S. Bell and Vivien H. C. Bramwell and George D. Demetri and Burton Larry Eisenberg and Christopher D M Fletcher and Jonathan A. Fletcher and Marc Ladanyi and Paul S. Meltzer and Brian O'Sullivan and David R. Parkinson and Peter W. T. Pisters and Scott Brian Saxman and Samuel Singer and Murali Sundaram and Allan T. van Oosterom and Jaap Verweij and Jill Waalen and Sharon Whelan Weiss and Murray F. Brennan},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  volume={9 6},
  • E. Borden, L. Baker, M. Brennan
  • Published 1 June 2003
  • Medicine, Biology
  • Clinical cancer research : an official journal of the American Association for Cancer Research
Sarcomas--like leukemias, which are also mesodermal malignancies--carry biological significance disproportionate to their clinical frequency. Identification of mutations and translocations associated with these tumors has illuminated aberrant signaling pathways that cause these diseases, determine their behavior, and are therapeutic targets. Activated receptor-associated tyrosine kinase c-kit, mutated in most gastrointestinal stromal tumors, has proven a clinically effective target for enzyme… 

Figures and Tables from this paper

Integrating the diagnosis of childhood malignancies.

  • D. Lopez-Terrada
  • Medicine, Biology
    Advances in experimental medicine and biology
  • 2006
The findings are consistent with a relationship between poor histologic phenotype and beta-catenin activation, indicating the potential utility of targeted gene expression assays to identify molecular events related to the pathogenesis and prognosis of hepatoblastomas.

Soft tissue sarcomas: From a morphological to a molecular biological approach

In vitro and in vivo studies of transcription factor Forkhead Box M1 (FOXM1) demonstrated the close correlation between aggressive biological behavior or chemosensitivity and FOXM1 expression in synovial sarcoma, so far, in regard to the investigation of cancer‐testis antigens.

Molecular pathology of sarcomas.

This review points out the clinical projection of sarcomagenesis elucidation and knowledge of diverse types of molecular alterations in sarcomas, as well as the identification of reliable molecular markers and possible therapeutic targets.

Role of Genetic and Molecular Profiling in Sarcomas

The overall goal of these types of techniques has been to determine a molecular blueprint for each sarcoma subtype and discover actionable alterations that lend themselves to targeted therapies.

The role of cytogenetics and molecular diagnostics in the diagnosis of soft-tissue tumors

  • J. Bridge
  • Medicine, Biology
    Modern Pathology
  • 2014
This review will address known recurrent or tumor-specific genetic events in soft-tissue tumors and discuss the molecular approaches commonly used in clinical practice to identify them and emphasis is placed on the role of molecular pathology in the management of soft-Tissue tumors.

Molecular diagnosis of sarcomas: chromosomal translocations in sarcomas.

In addition to the traditional diagnostic methods of examination of hematoxylin-eosin stained slides, immunohistochemistry, and sound clinical-pathologic correlation, additional cytogenetic and molecular biologic methods are being increasingly utilized and relied on in sarcoma pathology.

Soft Tissue Sarcomas with Special Reference to Molecular Aberration, Chemotherapy, and Recent Advances: A Review Article

The heterogeneity of STS has hindered the development of robust, evidence-based treatment strategies, and the therapeutic approach is neither histology-specific nor widely standardized, according to this review.

Recent advances in the molecular pathology of soft tissue sarcoma: Implications for diagnosis, patient prognosis, and molecular target therapy in the future

In malignant rhabdoid tumor and epithelioid sarcoma, frequent alteration of the SMARCB1/INI1tumor‐suppressor gene and the loss of its protein have been demonstrated, indicating that this molecule could be an effective target of these sarcomas.

Discovering novel oncogenic pathways and new therapies using zebrafish models of sarcoma.




Chromosomal translocations and sarcomas

Basic scientific findings are reviewed that elucidate the aberrant functions of SYT-SSX in chromatin remodeling and of EWS-FLI1 in transcription and mRNA splicing that will help identify new therapeutic targets.

Molecular Approaches to Sarcoma Therapy

This review summarizes published approaches targeting a specific molecular mechanism associated with sarcomagenesis and discusses the potential for improving outcomes in sarcoma patients and the conceptual obstacles to be overcome.

Contribution of molecular genetic data to the classification of sarcomas.

The focus of this brief review is the recent impact that the cytogenetic and molecular detection of these translocations has had on sarcoma diagnosis and classification.

Tumors associated with p53 germline mutations: a synopsis of 91 families.

The location of mutations within the p53 gene was found to be similar to that of somatic mutations in sporadic tumors, and there is no evidence of an organ or target cell specificity of p53 germline mutations; the occasional familial clustering of certain tumor types is more likely to reflect the genetic background of the respective kindred or the additional influence of environmental and nongenetic host factors.

Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile.

A remarkably distinct and uniform expression profile for all of the GISTs suggests that the molecular pathogenesis of a GIST results from expansion of a clone that has acquired an activating mutation in KIT without the extreme genetic instability found in the common epithelial cancers.

Alterations of cell cycle regulators in localized synovial sarcoma: A multifactorial study with prognostic implications.

EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma.

  • E. de ÁlavaA. Kawai M. Ladanyi
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1998
EWS-FLI1 fusion type appears to be prognostically relevant in ES, independent of tumor site, stage, and size.

EWS-FLI1 and Ewing’s Sarcoma: Recent Molecular Data and New Insights

Recent advances in three avenues of investigation are highlighted, namely the identification of various mitogenic targets of this aberrant transcription factor, its possible role as a deregulator of splicing, and the role of the p53 pathway in modulating its oncogenicity.

Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification.

Reclassified 100 tumors of the extremity and trunk wall primarily diagnosed as MFH confirmed that most so-called MFH can be subclassified by defined criteria; it provides evidence that such classification is clinically important.